KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Other financing activities (2016 - 2025)

Charles River Laboratories International (CRL) has 16 years of Other financing activities data on record, last reported at -$1.3 million in Q4 2025.

  • For Q4 2025, Other financing activities rose 70.61% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$14.0 million, up 55.4%, while the annual FY2025 figure was -$14.0 million, 55.4% up from the prior year.
  • Other financing activities reached -$1.3 million in Q4 2025 per CRL's latest filing, up from -$6.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at $28.7 million in Q1 2021 and bottomed at -$38.2 million in Q3 2021.
  • Average Other financing activities over 5 years is -$3.8 million, with a median of -$4.1 million recorded in 2023.
  • The widest YoY moves for Other financing activities: up 129.76% in 2022, down 263.77% in 2022.
  • A 5-year view of Other financing activities shows it stood at -$38.2 million in 2021, then soared by 95.51% to -$1.7 million in 2022, then tumbled by 141.97% to -$4.1 million in 2023, then dropped by 9.58% to -$4.5 million in 2024, then soared by 70.61% to -$1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were -$1.3 million in Q4 2025, -$6.2 million in Q3 2025, and -$6.5 million in Q2 2025.